This study is looking at how changes in your body's chemistry (metabolomics) and genetics might help in finding and understanding pancreatic neuroendocrine tumors (PNET) in people with Multiple Endocrine Neoplasia type 1 (MEN1). Researchers want to see if certain patterns in your blood can predict whether you will develop an aggressive PNET and how that might affect your survival. They will compare blood samples from MEN1 patients who developed aggressive PNETs with those who developed non-aggressive PNETs. This study aims to improve how doctors diagnose and monitor PNETs in MEN1 patients.

Study design

This is an observational study planning to include 629 participants. It is designed as a case-control study, comparing patients with aggressive PNETs to those with non-aggressive PNETs.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, the relationship of serum global metabolic profiles with subsequent development of aggressive PNET, will be measured at 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.